Literature DB >> 20674411

The role of surgical therapy in the management of intravenous bisphosphonates-related osteonecrosis of the jaw.

Frank Wilde1, Marcus Heufelder, Karsten Winter, Jörg Hendricks, Bernhard Frerich, Alexander Schramm, Alexander Hemprich.   

Abstract

OBJECTIVES: Bisphosphonate-related osteonecrosis of the jaw (BRONJ) seems resistant to conventional treatment approaches. We report a study with a surgical concept characterized by resection of the necrotic bone followed by sufficient wound closure. STUDY
DESIGN: In a clinical study of 24 patients with 33 sites of BRONJ, the surgical basis of the treatment was as follows: (1) conservative treatment with antimicrobiological rinsing, (2) resection of the entire necrotic bone and smoothening of any sharp bone edges, and (3) coverage of the remaining bone by use of a bilayered wound closure.
RESULTS: In 88% of cases, BRONJ could be treated with success by use of this surgical therapy. Median follow-up was 60 weeks. There was no statistically significant difference between treatment results irrespective of whether or not bisphosphonate treatment was continued.
CONCLUSION: Because of the high success rate of this surgical technique it seems that patients with BRONJ may benefit from this approach.
Copyright © 2011 Mosby, Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20674411     DOI: 10.1016/j.tripleo.2010.04.015

Source DB:  PubMed          Journal:  Oral Surg Oral Med Oral Pathol Oral Radiol Endod        ISSN: 1079-2104


  42 in total

Review 1.  Osteonecrosis of the jaw (ONJ): diagnosis and management in 2015.

Authors:  A Khan; A Morrison; A Cheung; W Hashem; J Compston
Journal:  Osteoporos Int       Date:  2015-10-22       Impact factor: 4.507

2.  Bisphosphonate-associated osteonecrosis of the mandible: reliable soft tissue reconstruction using a local myofascial flap.

Authors:  Juliana Lemound; Andrè Eckardt; Horst Kokemüller; Constantin von See; Pit Jacob Voss; Frank Tavassol; Martin Rücker; Majeed Rana; Nils-Claudius Gellrich
Journal:  Clin Oral Investig       Date:  2011-08-05       Impact factor: 3.573

3.  Teriparatide and the treatment of bisphosphonate-related osteonecrosis of the jaw: a rat model.

Authors:  N Ersan; L J van Ruijven; A L J J Bronckers; V Olgaç; D Ilgüy; V Everts
Journal:  Dentomaxillofac Radiol       Date:  2013-10-29       Impact factor: 2.419

4.  Treatment of stage II medication-related osteonecrosis of the jaw with necrosectomy and autologous bone marrow mesenchymal stem cells.

Authors:  Pit Jacob Voss; Akihiko Matsumoto; Esteban Alvarado; Rainer Schmelzeisen; Fabian Duttenhöfer; Philipp Poxleitner
Journal:  Odontology       Date:  2017-02-20       Impact factor: 2.634

Review 5.  A literature review of perioperative antibiotic administration in surgery for medication-related osteonecrosis of the jaw.

Authors:  Masaya Akashi; Junya Kusumoto; Daisuke Takeda; Takashi Shigeta; Takumi Hasegawa; Takahide Komori
Journal:  Oral Maxillofac Surg       Date:  2018-10-16

6.  Non-complex reconstructive techniques in the management of BRONJ: a case series of patient-related outcomes.

Authors:  Zaid Sadiq; Stephanie Sammut; Victor Lopes
Journal:  Oral Maxillofac Surg       Date:  2014-01-08

Review 7.  Surgical management of bisphosphonate-related osteonecrosis of the jaws: literature review.

Authors:  Larissa Fernandes Silva; Cláudia Curra; Marcelo Salles Munerato; Carlos Cesar Deantoni; Mariza Akemi Matsumoto; Camila Lopes Cardoso; Marcos Martins Curi
Journal:  Oral Maxillofac Surg       Date:  2015-12-11

8.  Tooth extraction in osteoporotic patients taking oral bisphosphonates.

Authors:  M Mozzati; V Arata; G Gallesio
Journal:  Osteoporos Int       Date:  2013-01-04       Impact factor: 4.507

9.  Bisphosphonates and osteonecrosis: an open matter.

Authors:  Paolo Vescovi
Journal:  Clin Cases Miner Bone Metab       Date:  2012-12-20

10.  Relevance of surgical management of patients affected by bisphosphonate-associated osteonecrosis of the jaws. A prospective clinical and radiological study.

Authors:  Philippe Lesclous; Sophie Grabar; Semaan Abi Najm; Jean-Pierre Carrel; Tommaso Lombardi; Jean-Louis Saffar; Jacky Samson
Journal:  Clin Oral Investig       Date:  2013-04-19       Impact factor: 3.573

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.